Clinical Trial Update: QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating QL1706-SOX versus SOX alone as neoadjuvant therapy for resectable diffuse-type gastric cancer (gastric cancer, stage III); status …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse-type Gastric Cancer
• Gastric Cancer

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• QL1706
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Gastric Cancer Stage III | Phase 2 | Status: NOT_YET_RECRUITING